Get the Stockscreener App
0.3995
0.62%
-0.0025
Soligenix Inc stock is traded at $0.3995, with a volume of 846.80K.
It is down -0.62% in the last 24 hours and down -2.23% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
See More
Previous Close:
$0.402
Open:
$0.4021
24h Volume:
846.80K
Relative Volume:
0.14
Market Cap:
$5.92M
Revenue:
$200.00K
Net Income/Loss:
$-10.95M
P/E Ratio:
-0.2024
EPS:
-1.9738
Net Cash Flow:
$-10.78M
1W Performance:
-7.31%
1M Performance:
-2.23%
6M Performance:
-67.52%
1Y Performance:
-77.62%
1-Day Range:
$0.3967
$0.4098
1-Week Range:
$0.3967
$0.45
52-Week Range:
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.3995 | 5.92M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Soligenix Inc (SNGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Soligenix Inc (SNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Soligenix Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats EstimatesRevenue Breakdown Analysis - newsline.com
Soligenix (SNGX) Hovers Near Key Support After Modest DeclineBearish Pattern Stocks - newsline.com
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy - TipRanks
Soligenix's Richard C. Straube ceases Consulting CMO role; duties moved to Christopher Pullion - TradingView
Soligenix (NASDAQ: SNGX) faces Nasdaq bid-price risk and ends HyBryte program - Stock Titan
SNGX Q1 2026 Earnings: EPS Beat Amid No Revenue, Stock DeclinesGross Profit Margin - newsline.com
Soligenix (SNGX) Bounces From Support: Biotech Stock Rises 3.5% to $0.44IV Contraction - newsline.com
Soligenix Stock Short Interest Rises to 43.99% - Quiver Quantitative
SNGX Q1 2026 Earnings: Narrower Loss Than Anticipated as Biotech Advances PipelineManagement Guidance Update - newsline.com
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus
Soligenix (SNGX) Pursues Vaccine Development for Bundibugyo Viru - GuruFocus
Soligenix (SNGX) stock soars 72% on ThermoVax platform promise amid Ebola outbreak caused by Bundibugyo virus - MSN
Soligenix applies for CEPI funding to develop thermostable vaccine for Bundibugyo Ebola virus. - Pluang
Soligenix (SNGX) Pursues Vaccine Development for Bundibugyo Virus - GuruFocus
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - PR Newswire
SNGX Stock Price, Quote & Chart - ChartMill
Soligenix (SNGX) Hovers Near Support With Slight DeclineRegression Channel - newsline.com
Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 – Company Information and Legal Exhibits - Minichart
Soligenix Expands At-The-Market Equity Financing Capacity - TipRanks
Soligenixincreases maximum offering under sales agreement by $2.96 million - marketscreener.com
Soligenix raises at‑market share capacity by $2.956M under sales agreement - TradingView
Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96M - Stock Titan
Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreement - Stock Titan
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Soligenix Company Profile & Introduction - Moomoo
Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update - Quiver Quantitative
$AIM ImmunoTech (AIM.US)$ easiest money i ever made $Soligenix (SNGX.US)$ you 2 booboo - Moomoo
Soligenix (SNGX) Stock Soars 110% as Ebola Outbreak Puts Vaccine Hopes on the Table - MEXC
SNGX Stock Pops On Heavy Volume As Traders Hunt Volatility - StocksToTrade
Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play - TechStock²
$Soligenix (SNGX.US)$ - Moomoo
Top Premarket Gainers - Moomoo
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy - Yahoo Finance
Trending Stocks Today | Soligenix Soars 133.91% Pre-Market - Moomoo
$Soligenix (SNGX.US)$ checkmate [Share Link: Join us in the TradersLink chat.] - Moomoo
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo V - Benzinga
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - Lelezard
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus - Sahm
$Soligenix (SNGX.US)$ thank - Moomoo
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock SlipsTop Trending Breakouts - Newser
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Soligenix (SNGX) Down -5.08% — Is the Sell-Off Overdone? 2026-05-21Retail Trader Picks - Newser
Soligenix (SNGX) price target decreased by 60.00% to 6.12 - MSN
Soligenix (SNGX) Crushes Q4 2025 Estimates — EPS $-0.28 Tops ViewsIntrinsic Value - Newser
TradingKey - TradingKey
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - USA Today
Soligenix | 424B3: Prospectus - Moomoo
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):